As of May, 24 The EPS for BioLineRx Ltd. (BLRX) Expected At $-0.07

May 16, 2018 - By Jenna Rose

BioLineRx Ltd. (NASDAQ:BLRX) Corporate Logo

Investors wait BioLineRx Ltd. (NASDAQ:BLRX)’s quarterly earnings on May, 24., RTT reports. EPS of $-0.07 is 12.50 % up from 2017’s $-0.08 EPS. Last quarter $-0.07 EPS was reported. Analysts sees 0.00 % EPS growth this quarter. BLRX is reaching $0.8863 during the last trading session, after increased 8.09%.BioLineRx Ltd. is downtrending after having declined 24.35% since May 16, 2017. BLRX has 1.34 million volume or 509.36% up from normal. BLRX underperformed by 35.90% the S&P500.

BioLineRx Ltd. (NASDAQ:BLRX) Ratings Coverage

In total 2 analysts cover Biolinerx (NASDAQ:BLRX). “Buy” rating has 2, “Sell” are 0, while 0 are “Hold”. (NASDAQ:BLRX) has 100% bullish analysts. 9 are the (NASDAQ:BLRX)’s ratings reports on May 16, 2018 according to StockzIntelligence Inc. On Tuesday, March 20 the stock of BioLineRx Ltd. (NASDAQ:BLRX) has “Buy” rating given by Oppenheimer. On Monday, December 4 the stock has “Buy” rating by Oppenheimer. On Thursday, December 21 H.C. Wainwright maintained BioLineRx Ltd. (NASDAQ:BLRX) rating. H.C. Wainwright has “Buy” rating and $4.0 target. On Tuesday, March 6 the rating was maintained by Oppenheimer with “Buy”. On Tuesday, November 21 H.C. Wainwright maintained BioLineRx Ltd. (NASDAQ:BLRX) with “Buy” rating. The company rating was maintained by H.C. Wainwright on Tuesday, March 6. The company rating was maintained by H.C. Wainwright on Wednesday, January 17. On Monday, December 4 H.C. Wainwright maintained BioLineRx Ltd. (NASDAQ:BLRX) with “Buy” rating. On Thursday, December 21 the rating was initiated by Oppenheimer with “Buy”.

BioLine Rx Ltd, a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs.The firm is valued at $93.94 million. The Company’s development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions.Last it reported negative earnings. The company's other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome.

More recent BioLineRx Ltd. (NASDAQ:BLRX) news were posted by Benzinga.com, Benzinga.com and Benzinga.com. The first one has “Benzinga Pro’s 5 Stocks To Watch Today” as a title and was posted on May 16, 2018. The next is “BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid …” on May 16, 2018. And last was posted on May 16, 2018, called “40 Stocks Moving In Wednesday’s Mid-Day Session”.

BioLineRx Ltd. (NASDAQ:BLRX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: